EPHA2 and cancer: A similar response was reported by Carles–Kinch et al (2002) who identified an EphA2 mAb that recognizes a binding site present only in EphA2-positive cancer cells and reverses metastatic behaviour by activating the high levels of EphA2 on a tumour cell surface [49].